Latest United States News

Telix reported US$245 million in unaudited third-quarter revenue, with Precision Medicine sales up 30% and full-year revenue and other income still expected to exceed US$1 billion. The quarter also advanced the proposed US$1.65 billion ITM merger, added FDA-approved Pixclara to the commercial portfolio and narrowed the R&D spending range.

CurveBeam AI has secured its strongest first-quarter HiRise sales result, gained China regulatory clearance and raised A$7.35 million to fund the next stage of commercialisation. The progress comes alongside lower customer receipts and a reported 4.3 quarters of cash runway.

BPH Energy’s latest quarter puts its portfolio risks in sharp relief: Advent is appealing the PEP11 ruling while another subsidiary remains in voluntary administration. BPH ended September with $1.127 million in cash, but deployed $972,000 in loans to investees during the quarter.

EBR Systems has submitted its WiSE wireless cardiac pacing system for Australian regulatory approval, opening a potential second commercial market after the United States. The application has entered a priority review pathway, but neither approval nor an assessment timetable is guaranteed.

Blackpearl Group narrowed its quarterly EBITDAF loss to $2.97 million and is now targeting profitability in Q1 FY28. The company has also secured a non-binding US distribution agreement with a potential pipeline of more than 70 enterprise customers.

AdAlta expects an additional R&D Tax Incentive refund of more than A$1 million after securing approval for specified overseas work on its EW-001 CAR-T therapy. The cash benefit arrives as the company prepares for a US FDA pre-IND meeting in November.

Australian Vintage has returned to positive operating cash flow, but its FY26 statutory loss widened sharply after a $27 million inventory write-down and deferred tax charge. The wine group is betting that Poco Vino growth, further restructuring and lower stock levels can convert the cash improvement into debt reduction in FY27.

Firebrick Pharma has secured Philippine marketing approval for Nasodine Nasal Spray as an over-the-counter antiseptic, opening a potential launch in the 116 million-person market from early 2027. The approval remains subject to post-approval documentation and future revalidation.

Paradigm has reported a strong pain and function signal for iPPS outside the US, including a 1.105-point advantage over placebo at Day 112. The result does not revive the halted Phase 3 trial, with the company under administration and a potential funding proposal still unreceived.

Titomic will restructure its Australian and US operations and reduce consultant spending, targeting A$3.0 million in annualised operating cost savings. The company expects to complete the changes by October’s end while repositioning Australia as its global research and development centre.

ARB Corporation’s FY26 profit fell 5.2% as weaker Australian aftermarket and OEM sales outweighed modest export growth. The 4x4 accessories maker is relying on improved vehicle supply, US expansion and new product programs to rebuild momentum in FY27.

Energy Fuels has amended its proposed acquisition of VAC after a customer dispute escalated into arbitration and lender forbearance at VAC’s US magnet plant. The filing also reveals VAC’s six-month net loss of €57.4 million, substantial debt and reliance on shareholder support ahead of the proposed transaction.